INVESTORS

Investor Relations

Recent News
Apr 3, 2019
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019

- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA),...

Apr 1, 2019
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019

- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung...

Mar 5, 2019
Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston

- Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019 - VANCOUVER, March 5, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

View all news releases

Events and Webcasts
Cowen 39th Annual Health Care Conference
Wednesday, March 13, 2019
10:00am EDT

Date: March 13, 2019 Time: 10:00 am ET Location: Boston, MA

View all events and webcasts

Annual Meeting of Stockholders

Date: Tuesday, June 11, 2019
Time: 10:00 am PT
Location: Four Seasons Hotel, 791 West Georgia Street, Vancouver, British Columbia V6C 2T4

Materials:

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts


NASDAQ: SRRANASDAQ: DNAI